

Brian A Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/775408/publications.pdf>

Version: 2024-02-01

26
papers

8,891
citations

516710

16
h-index

580821

25
g-index

29
all docs

29
docs citations

29
times ranked

9767
citing authors

#	ARTICLE	IF	CITATIONS
1	Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. <i>Science</i> , 2000, 289, 739-745.	12.6	5,486
2	IL-28, IL-29 and their class II cytokine receptor IL-28R. <i>Nature Immunology</i> , 2003, 4, 63-68.	14.5	1,385
3	The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. <i>Journal of Experimental Medicine</i> , 2009, 206, 1495-1503.	8.5	566
4	Improved recognition of native-like protein structures using a combination of sequence-dependent and sequence-independent features of proteins. , 1999, 34, 82-95.		389
5	Vstm3 is a member of the CD28 family and an important modulator of T cell function. <i>European Journal of Immunology</i> , 2011, 41, 902-915.	2.9	285
6	X-Ray Diffraction Analysis of Three-Dimensional Crystals of Bovine Rhodopsin Obtained from Mixed Micelles. <i>Journal of Structural Biology</i> , 2000, 130, 73-80.	2.8	176
7	Identification of the Calcium Binding Site and a Novel Ytterbium Site in Blood Coagulation Factor XIII by X-ray Crystallography. <i>Journal of Biological Chemistry</i> , 1999, 274, 4917-4923.	3.4	98
8	Validation of a Host Response Assay, SeptiCyt [®] LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 903-913.	5.6	87
9	The Role of Genomic Data in the Discovery, Annotation and Evolutionary Interpretation of the Interferon-Lambda Family. <i>PLoS ONE</i> , 2009, 4, e4933.	2.5	68
10	High-Resolution Gene Expression Profiling Using RNA Sequencing in Patients With Inflammatory Bowel Disease and in Mouse Models of Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 492-506.	1.3	57
11	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. <i>Blood Advances</i> , 2022, 6, 2219-2229.	5.2	40
12	Increased serum β_2 -microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. <i>Lupus</i> , 2012, 21, 1098-1104.	1.6	34
13	Cytokine-receptor pairing: accelerating discovery of cytokine function. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 160-170.	46.4	33
14	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. <i>PLoS Medicine</i> , 2020, 17, e1003323.	8.4	33
15	Genome sequence of a diabetes-prone rodent reveals a mutation hotspot around the ParaHox gene cluster. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7677-7682.	7.1	30
16	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 2207-2218.	5.2	24
17	Blood transcriptomic discrimination of bacterial and viral infections in the emergency department: a multi-cohort observational validation study. <i>BMC Medicine</i> , 2020, 18, 185.	5.5	20
18	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2022, 115, 222-232.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Integrative network modeling reveals mechanisms underlying T cell exhaustion. <i>Scientific Reports</i> , 2020, 10, 1915.	3.3	14
20	Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2013, 23, 729-740.	1.8	11
21	Depletion of regulatory T cells leads to an exacerbation of delayed-type hypersensitivity arthritis in C57BL/6 mice that can be counteracted by IL-17 blockade. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 427-40.	2.4	10
22	Improved recognition of native-like protein structures using a combination of sequence-dependent and sequence-independent features of proteins. <i>Proteins: Structure, Function and Bioinformatics</i> , 1999, 34, 82-95.	2.6	9
23	Applying genetics in inflammatory disease drug discovery. <i>Drug Discovery Today</i> , 2015, 20, 1176-1181.	6.4	6
24	Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model. <i>Arthritis Research and Therapy</i> , 2016, 18, 28.	3.5	6
25	Generation of a high-affinity Fcγ receptor by Ig-domain swapping between human CD64A and CD16A. <i>Protein Engineering, Design and Selection</i> , 2010, 23, 299-309.	2.1	4
26	Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 16460.	3.3	3